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Retroviral vectors containing inducible promoters will be useful for gene therapy and other situations in experimental biology in which the stable integration and expression of an inducible operon is required. One candidate for this use is a system of cytokine-inducible gene expression, the JAK (janus kinase)-STAT (signal transducers and activators of transcription) system, that is activated by the binding of certain ligands, including interleukins, interferons, and hematopoietic colonystimulating factors, to their cognate cell surface receptors. 1 Ligand binding induces the aggregation and crossphosphorylation of JAKs, which subsequently phosphorylate STATs. The phosphorylated STATs translocate to the nucleus and bind to specific sequences in the promoters of target genes, activating gene transcription. Previous work by others has demonstrated that insertion of multimers of the core sequence 5Ј-TTCCCGGAA imparts inducibility by interferon-␥ (IFN-␥), interleukin-4 (IL-4), interleukin-6 (IL-6), and granulocyte-macrophage colony-stimulating factor (GM-CSF) to the minimal thymidine kinase promoter. 2, 3 We hypothesized that the insertion of STAT-binding elements into the retroviral promoter/enhancer (unique 3Ј long terminal repeat sequences, U3) would lead to cytokine-inducible expression from an integrated retroviral vector.
A major limitation in the use of retroviral vectors for gene expression in vivo is the high frequency with which transgene expression is attenuated. One approach to the Correspondence: RL Saylors Received 3 September 1998; accepted 25 November 1998 optimization of gene expression in undifferentiated cells has been to search for naturally occurring retroviral mutants that express well in these cell types. One such mutant virus, the myeloproliferative sarcoma virus (MPSV), contains a point mutation (A to C) at a point −166 from the transcriptional start site. This mutation creates a consensus binding site for the Sp1 transcription factor and has been shown to bind Sp1 in vitro. 4, 5 Because the Sp1 protein is expressed at very high levels in developing cells, including primitive hematopoietic cells, binding of the Sp1 protein to the U3 promoter/enhancer may provide a stimulus for long-term in vivo expression after transfer of the construct to hematopoietic cells by retrovirus-mediated gene transfer. 6 A recent report demonstrated the use of a MPSV-based vector, which carries the Sp1 mutation described above, to express human alkyltransferase in murine bone marrow cells in vivo. 7 We used the polymerase chain reaction (PCR) to create the MPSV Sp1 mutation in the Moloney murine leukemia virus (MoMuLV) U3 and inserted multimers of a STATbinding oligonucleotide into this Sp1-containing U3 (Figure 1a) . In order to quantify the effect of cytokine administration on the level of gene expression from the Sp1 and STAT-containing MoMuLV U3s in the context of an integrated provirus, the MoMuLV U3s containing the Sp1 mutation, with or without multimers of the STAT oligo, were cloned into the novel LLucEN retroviral vector that co-expresses the luciferase and neomycin phosphotransferase genes (Figure 1b) . In preliminary experiments using a plasmid-based expression vector system, we found that the addition of one, three, five, six or eight STAT oligos to the Sp1 U3 resulted in decreased levels 
(b) The parent retroviral vector LEN was constructed by inserting a cassette containing the IRES from the 5Ј untranslated region of encephalomyocarditis virus (emc) fused to the neomycin phosphotransferase (neo) gene into the LN backbone.
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(d) Luciferase expression in the absence and presence of IFN-␥ was determined as in (c) at 1, 3, 6 and 9 months after transduction and selection.
of inducibility as compared with the Sp1 U3 containing two or four STAT binding oligos (data not shown). Therefore, we chose the Sp1 U3 containing no, two or four STAT oligos (Sp1, Sp1/STATx2, Sp1/STATx4) for analysis in the context of an intact retroviral vector and compared these data with those obtained from the wild-type (WT) U3.
Stable pools of HepG2 cells transduced with the retroviruses were generated using conditions favorable for single transduction events, selected with G418, and expanded. Figure 1c demonstrates the basal and IFN-␥-induced levels of luciferase expressed by the transduced retroviral constructs after 6 months of continuous culture in the presence of G-418. The Sp1/STATx4 vector gave the highest level of induction in this system, with a value of 9.9-fold induction when compared with the uninduced vector. When the Sp1/STATx4 vector was compared with the WT and Sp1 vectors, respective values of 17.9-and 16.7-fold higher expression were achieved with IFN-␥ treatment. Figure 1d shows sequential expression data collected for the Sp1/STATx4 construct, in the presence and absence of IFN-␥ induction, demonstrating that the vectors mediate stable basal and IFN-␥ inducible transgene expression in vitro.
It has been noted previously that directly repeated segments included within the retroviral U3 are sometimes unstable. 8 In order to verify that the STAT oligos were present in the expected numbers in the proviral U3s after transduction, we performed Southern blots on genomic DNA from the transduced HepG2 pools. The DNA was digested with NheI and XmaI, which cleaves the U3 from the integrated provirus, and probed with the end-labeled Sp1 sense oligo (5Ј-GTCCCGCCCTCAGCAGTTTCT). This oligo is homologous to all of the Sp1 mutant U3s and differs by only a single C residue from the wild-type U3 sequence. As shown in Figure 2 , both the Sp1/STATx2 and Sp1/STATx4 proviruses are of the size predicted from the insertion of two or four STAT oligos, indicating that the inserted STAT elements are stable through at least 6 months of passage in tissue culture.
The goal of these experiments was to construct retroviral U3s that drive high level basal gene expression and that allow further increases in gene expression after induction with cytokines. The Sp1 mutation we used has been used by other investigators in the area of hematopoietic stem cell progenitor gene transfer. This mutation permits gene expression in previously non-permissive cell types and will likely result in long-term gene expression in vivo. 4, 5, 7 The use of STAT-responsive elements has been shown by other investigators to confer cytokine responsiveness to minimal promoters. 2, 3 We show here that the combination of Sp1-and STATresponsive elements in the MoMuLV U3 results in up to 9.9-fold inducibility with IFN-␥. When compared with the vectors that do not contain STAT-binding sites, further increases in expression of 16.7-to 17.9-fold are possible, the higher level of these values being due to the relatively lower level of basal activity of the constructs that lack STAT sites. The effects of these mutations on long-term basal and cytokine-inducible expression in vivo is currently under investigation.
Retroviral vectors incorporating Sp1-and STATresponsive elements into the U3 will be useful in a number of clinical situations in which the induction of supraphysiologic levels of gene expression is beneficial. Potential examples include gene therapy for diseases such as chronic granulomatous disease, where the stress of infection, with the resultant production of cytokines that activate the JAK-STAT pathway, could generate increased superoxide from vectors containing STAT responsive U3s. 9, 10 These vectors will also be useful in the expression of genes in T cells, where the transduction of IL-2 signals via the IL-2R will result in increased expression of the gene carried in the Sp1/STAT vector, and in myeloid leukemia cells, where constitutive activation of STATs will allow for high basal levels of gene expression. Lastly, the administration of pharmacologic doses of cytokines, such as GM-CSF, that increase the number of marrow and circulating hematopoietic cells, will increase levels of gene product by increasing cell number, as well as by the induction of gene expression in each hematopoietic cell transduced by the Sp1/STAT vectors.
